Loading…
IGC Pharma, Inc. is projected to rise to $0.3769 by 2027, a +30% move from its current price of $0.29. IGC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.2835 | $0.2901 | $0.2969 | +0.04% |
| May 30 | $0.2809 | $0.2902 | $0.2998 | +0.08% |
| May 31 | $0.279 | $0.2904 | $0.3022 | +0.12% |
| Jun 1 | $0.2774 | $0.2905 | $0.3041 | +0.16% |
| Jun 2 | $0.276 | $0.2906 | $0.3059 | +0.20% |
| Jun 3 | $0.2748 | $0.2907 | $0.3076 | +0.24% |
| Jun 4 | $0.2737 | $0.2908 | $0.3091 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2737 | $0.2908 | $0.3091 | +0.28% |
| Week 2 | $0.2676 | $0.2917 | $0.3179 | +0.57% |
| Week 3 | $0.2632 | $0.2925 | $0.325 | +0.86% |
| Week 4 | $0.2597 | $0.2933 | $0.3313 | +1.14% |
| Week 5 | $0.2567 | $0.2942 | $0.337 | +1.43% |
| Week 6 | $0.2541 | $0.295 | $0.3424 | +1.72% |
| Week 7 | $0.2518 | $0.2958 | $0.3475 | +2.01% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
IGC Pharma, Inc. is a clinical stage pharmaceutical company focused on neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. Its lead product is IGC-AD1, which is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.
Its pre-clinical stage product candidates include TGR-63 and IGC-M3 to treat Alzheimer's disease. The company also develops MINT-AD, an AI-driven assistant for healthcare providers.
The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
IGC Pharma, Inc. (IGC) is trading at $0.288. It is ranked 4,822 by market capitalization and has a market cap of $28.83M.
The near-term price outlook is informed by the current technical picture, which shows a bearish tone with RSI 14 at 40, and key moving averages positioned with SMA50 at $0.2968 and SMA200 at $0.3314. Support sits at $0.28 and resistance at $0.35, with a 30-day range of $0.2451 to $0.3384.
The multi-year forecast begins with a neutral 2026, then adopts a bullish trajectory through 2027 to 2050, with the average price rising from $0.288 in 2026 to $1.62 in 2050 and a total return on investment of 463.2% by 2050.
A major floor 18.4% below — a decisive break under it would weaken the trend.
The nearest floor, 3.4% below — buyers have tended to step in here.
The nearest ceiling, 20.7% above — a clean break opens room to run.
A major ceiling 29.9% above — clearing it would confirm fresh momentum.
Key IGC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IGC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.288 | Buy | $0.2894 | Buy |
| MA 10 | $0.29 | Buy | $0.2922 | Sell |
| MA 20 | $0.3025 | Sell | $0.2978 | Sell |
| MA 50 | $0.2972 | Sell | $0.2985 | Sell |
| MA 100 | $0.2886 | Buy | $0.3015 | Sell |
| MA 200 | $0.3309 | Sell | $0.3141 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.72 | Neutral |
| Stoch RSI (14) | 39.18 | Neutral |
| CCI (20) | -64.10 | Neutral |
| Williams %R (14) | -75.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -6.45 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 25.00 | Neutral |
| TRIX (15) | -0.13 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 40.30 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 0.29 | Sell |
| ADX (14) | 17.13 | Neutral |
| ATR (14) | 0.00 | Info |
Bearish sentiment is reflected in the near-term technicals. RSI14 is 40, and the price sits below SMA50 ($0.2968) while SMA200 stands higher at $0.3314. The stock trades within a 30-day range of $0.2451 to $0.3384, with explicit support at $0.28 and resistance at $0.35.
Overall near-term risk appears elevated given the bearish tilt, but a defined downside protection at the $0.28 level provides a clear area to monitor for potential changes in momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.25 | $0.29 | $0.38 | 0% | Neutral | |
| $0.3035 | $0.3769 | $0.493 | +30% | Bullish | |
| $0.323 | $0.4103 | $0.5534 | +41% | Bullish | |
| $0.3324 | $0.4301 | $0.5946 | +48% | Bullish | |
| $0.3399 | $0.4472 | $0.6311 | +54% | Bullish | |
| $0.3531 | $0.4716 | $0.6778 | +63% | Bullish | |
| $0.3699 | $0.5011 | $0.7321 | +73% | Bullish | |
| $0.398 | $0.5462 | $0.8101 | +88% | Bullish | |
| $0.4779 | $0.664 | $0.9985 | +129% | Bullish | |
| $0.5126 | $0.7208 | $1.10 | +149% | Bullish | |
| $0.666 | $0.988 | $1.59 | +241% | Bullish | |
| $1.05 | $1.70 | $2.97 | +487% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.25 | $0.29 | $0.3394 | +0.00% |
| June 2026 | $0.2499 | $0.2925 | $0.3497 | +0.85% |
| July 2026 | $0.2553 | $0.3009 | $0.3639 | +2.90% |
| August 2026 | $0.2514 | $0.2979 | $0.3635 | -1.00% |
| September 2026 | $0.2449 | $0.2916 | $0.3583 | -2.12% |
| October 2026 | $0.2496 | $0.2984 | $0.369 | +2.32% |
| November 2026 | $0.2552 | $0.3062 | $0.3809 | +2.63% |
| December 2026 | $0.2524 | $0.3039 | $0.38 | -0.76% |
Click any year to see its month-by-month IGC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IGC could reach as high as $0.38, with a base case around $0.29 and support toward $0.25 — roughly 0% from $0.29. Price action looks broadly range-bound.
Expect IGC to range from $0.3035 to $0.493 through 2027. The $0.3769 average target implies a +30% move from current prices. That is up +30% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The IGC price prediction for 2028 points to an average of $0.4103 (low $0.323, high $0.5534) — a potential gain of +41% on today's $0.29. Momentum favours further upside here.
In 2029, IGC is projected to trade between $0.3324 and $0.5946, averaging $0.4301 — a potential gain of +48% from today's $0.29. That is up +5% on the projected 2028 average. Buyers look set to stay in control over this stretch.
IGC Pharma, Inc.'s 2030 outlook centres on $0.4472, within a $0.3399 to $0.6311 range. That is up +4% on the projected 2029 average. That marks a +54% change versus current levels. Momentum favours further upside here.
By 2031, IGC could reach as high as $0.6778, with a base case around $0.4716 and support toward $0.3531 — roughly +63% from $0.29. Buyers look set to stay in control over this stretch.
Expect IGC to range from $0.3699 to $0.7321 through 2032. The $0.5011 average target implies a +73% move from current prices. That is up +6% on the projected 2031 average. Momentum favours further upside here.
The IGC price prediction for 2033 points to an average of $0.5462 (low $0.398, high $0.8101) — a potential gain of +88% on today's $0.29. Buyers look set to stay in control over this stretch.
In 2034, IGC is projected to trade between $0.4779 and $0.9985, averaging $0.664 — a potential gain of +129% from today's $0.29. That is up +22% on the projected 2033 average. Momentum favours further upside here.
IGC Pharma, Inc.'s 2035 outlook centres on $0.7208, within a $0.5126 to $1.10 range. That is up +9% on the projected 2034 average. That marks a +149% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, IGC could reach as high as $1.59, with a base case around $0.988 and support toward $0.666 — roughly +241% from $0.29. Momentum favours further upside here.
Expect IGC to range from $1.05 to $2.97 through 2050. The $1.70 average target implies a +487% move from current prices. That is up +72% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IGC today (≈ 3,448.275862 IGC) could be worth
$5,872.27
+$4,872.27 (+487%) by 2050 · US Dollar
Based on the average projected IGC price of $1.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IGCwould be worth at today's price.
$1,000 invested in IGC on May 27, 2025 (≈ 3,030.30291 IGC) would be worth
$878.79
-$121.21 (-12.1%) today · 0.88× · US Dollar
Based on a IGC entry price of $0.33 vs. today's $0.29.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.28 | $1,035.71 | +3.6% |
| 1 month ago | $0.32 | $906.25 | -9.4% |
| 3 months ago | $0.28 | $1,035.71 | +3.6% |
| 6 months ago | $0.32 | $906.25 | -9.4% |
| 1 year ago | $0.33 | $878.79 | -12.1% |
| All time (5.0y) ago | $1.45 | $200 | -80.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IGC forecast.
Our base-case forecast reaches $0.58 around 2034.
Implied market cap at $0.58: $58.05M
The long-term forecast shows a clear path of appreciation, with the average price moving from $0.288 in 2026 to $1.62 by 2050. Notable milestones include 2030 avg $0.4413 with a 53.2% ROI, 2040 avg $0.9495 with a 229.7% ROI, and 2050 avg $1.62 with a 463.2% ROI. The yearly sentiment shifts from Neutral in 2026 to Bullish from 2027 onward, signaling increasing upside potential over time.
From a higher-level view, the forecast also indicates higher potential price ceilings, with 2035 max $1.08, 2040 max $1.55, and 2050 max $2.88, all within a bullish framework. These are estimates and not guarantees; actual performance will depend on market conditions, regulatory developments, and clinical outcomes, among other factors. The forecast carries inherent uncertainty, especially in the near term opposite a rising long-term bullish trajectory.
Tap a question to reveal the answer.
In 2030, the forecast lists min $0.3323, avg $0.4413, max $0.6301 with a 53.2% ROI and bullish sentiment.
The outlook shifts from Neutral in 2026 to Bullish from 2027 onward, with the average price rising to $1.62 by 2050 and a 463.2% ROI. However, these are estimates, not guarantees.
Yes. The forecast shows 2035 max $1.08, 2040 max $1.55, and 2050 max $2.88, indicating potential to surpass $1 in several later years.
Current price is $0.288 and market cap is $28.83M. The asset is ranked 4,822 by market capitalization.
The 2050 forecast shows avg $1.62, min $0.9723, max $2.88 with a 463.2% ROI and bullish sentiment.
IGC Pharma, Inc. Community Discussion
0Share your IGC Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.